TWST - NASDAQ
Twist Bioscience Corporation
$76.92
+6.8%Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotTwist Bioscience Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Twist Bioscience Corporation Income Statement
TWST • NASDAQ
| Twist Bioscience Corporation Income Statement | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
376.6M | 313M | 245.1M | 203.6M | 132.3M | 90.1M | 54.4M | 25.4M | 10.8M | 2.3M | |
GROSS PROFIT | ||||||||||
(185.6M) | (179.6M) | (155.4M) | (119.3M) | (80.6M) | (61.4M) | (47.4M) | (32.2M) | (24M) | (9.4M) | |
191M | 133.3M | 89.7M | 84.2M | 51.7M | 28.7M | 7M | -6.8M | -13.3M | -7.2M | |
OPERATING INCOME | ||||||||||
(327.3M) | (354.2M) | (306.9M) | (319M) | (204.4M) | (146.3M) | (115.8M) | (63.8M) | (45.2M) | (36.5M) | |
(247M) | (218.4M) | (189.7M) | (212.9M) | (135.9M) | (103.3M) | (80.1M) | (43.5M) | (26.1M) | (18.3M) | |
(80.3M) | (90.9M) | (106.9M) | (120.3M) | (69.1M) | (43M) | (35.7M) | (20.3M) | (19.2M) | (18.2M) | |
-136.3M | -220.8M | -217.2M | -234.8M | -152.7M | -117.6M | -108.9M | -70.6M | -58.5M | -43.7M | |
PRE-TAX INCOME | ||||||||||
(0.0) | (29K) | (5K) | (80K) | (367K) | (787K) | (1.3M) | (1.3M) | (905K) | (746K) | |
11.4M | 15.3M | 14.4M | 3M | 68K | 712K | 1.7M | -314K | -493K | -505K | |
(0.0) | (44.9M) | (10.3M) | -14.2M | -534K | -182K | -265K | -121K | -55K | (73K) | |
59.3M | 12.7M | 13.7M | 6.5M | -1.3M | 530K | 1.5M | -435K | -548K | -432K | |
-77M | -208.2M | -203.5M | -228.3M | -154M | -139.5M | -107.4M | -71M | -59M | -44.1M | |
NET INCOME | ||||||||||
(719K) | (560K) | (1.2M) | -10.4M | -1.9M | (382K) | (292K) | (242K) | (280K) | (0.0) | |
-77.7M | -208.7M | -204.6M | -217.9M | -152.1M | -139.9M | -107.7M | -71.2M | -59.3M | -44.1M |
SEC Filings
TWST - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
10-Q/A 10-Q/A 2025 Q4 (Amended) Q4 | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 06, 2026 | February 05, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 02, 2026 | February 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | January 06, 2026 | February 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | November 17, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your TWST research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.